News | Ventricular Assist Devices (VAD) | June 08, 2022

Medtronic Recalls HVAD Pump Implant Kit for Pump Weld Defect

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the HVAD Pump Implant Kit due to a pump weld defect.

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the HVAD Pump Implant Kit due to a pump weld defect. Following an inspection of explanted pumps returned to Medtronic, an analysis showed moisture had entered the center post of the pump causing corrosion and demagnetization of the internal magnets, which may cause the pump to rotate incorrectly.

This issue can lead to pump malfunction, death, or severe injury (for example: shock with severe organ dysfunction, stroke), or require patients to undergo major surgery to replace the pump.

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product

  • Product Name: HVAD Pump Implant Kit
  • Models: 1101, 1103, 1104, 1104JP, MCS1705PU
  • Distribution Dates: October 11, 2006 to June 3, 2021
  • Devices Recalled in the U.S.: 1,614
  • Date Initiated by Firm: April 11, 2022

Device Use

The HeartWare Ventricular Assist Device (HVAD) System is used to help the heart continue to pump blood to the rest of the body. The HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery, or as destination therapy (DT) in patients for whom heart transplants are not planned.

Reason for Recall

Medtronic is recalling the HVAD Pump Implant Kit due to a pump weld defect. Following an inspection of explanted pumps returned to Medtronic, an analysis showed moisture had entered the center post of the pump causing corrosion and demagnetization of the internal magnets, which may cause the pump to rotate incorrectly. Patients with affected devices may present with signs and symptoms that resemble pump thrombosis.

If this issue occurs, it may lead to pump malfunction, death, or severe injury (for example: shock with severe organ dysfunction, stroke), or require patients to undergo major surgery to replace the pump.

Medtronic has received three complaints regarding this device issue, including one death, and two injuries.

Who May be Affected

  • Health care providers using the Heartware HVAD System
  • Patients who have procedures with the Heartware HVAD System

What to Do

On April 11 2022, Medtronic sent an Urgent Medical Device Correction letter to select physicians and health care providers who have unused HVAD Pump Implant Kits to request that the product be returned.

On April 26, 2022, Medtronic sent an Urgent Medical Device Correction letter to all physicians and health care providers to inform them of this potential pump weld defect.

The letter requested customers to:

  • Upload and submit all .csv logfiles to Medtronic when patients present with the signs and symptoms listed in the letter.
  • Consider whether patients presenting with any of the signs and symptoms listed in the letter could be caused by a pump thrombus and treat accordingly. Physicians should make decisions about removing or exchanging the pump on a case-by-case basis, considering the patient's clinical condition and surgical risks.
  • Share the letter with all those who need to be aware within their organization or any organization where potentially affected patients have been transferred.
  • Complete the enclosed Customer Confirmation Form and email to [email protected].

Contact Information

Health care providers with questions about this recall should contact their local Medtronic Representative.

Patients with questions about this recall should contact Medtronic Patient Services at 800-635-3930 (Monday-Friday, 8 a.m. to 5 p.m. Central time).

Related HVAD Content:

Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries

Class I Recall Issued for Medtronic HeartWare HVAD Pump

Medtronic HeartWare HVAD System Approved for Destination Therapy

FDA, Medtronic Expand HeartWare VAD Recall, Announces New Recall of VAD Component

FDA Announces Two HeartWare HVAD System Class 1 Recalls

New Heart Assist Pump Allows Minimally Invasive Approach at Vanderbilt Heart and Vascular Institute


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now